Javier Aleman Porto
Family · Winter Haven, FLNPI 1417413964
Payments from drug & device makers
Across 300 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$467
- AbbVie$459
- AstraZeneca$459
- GSK$423
- Novo Nordisk$422
- Pfizer$380
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,689100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 26 | $467 |
| AbbVie | 24 | $459 |
| AstraZeneca | 27 | $459 |
| GSK | 23 | $423 |
| Novo Nordisk | 22 | $422 |
| Pfizer | 20 | $380 |
| Lilly USA, LLC | 17 | $340 |
| Boehringer Ingelheim | 15 | $302 |
| Merck | 14 | $295 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $237 |
| E.r. Squibb & Sons, L.L.C. | 11 | $215 |
| Bayer | 10 | $206 |
| Dexcom, Inc. | 9 | $165 |
| Abbott | 7 | $146 |
| Johnson & Johnson | 7 | $133 |
| Esperion Therapeutics, Inc. | 6 | $126 |
| Exact Sciences | 6 | $125 |
| Biohaven Pharmaceuticals, Inc. | 6 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $86 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Novartis | 3 | $58 |
| Eisai Inc. | 3 | $57 |
| Astellas Pharma US Inc | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $53 |
| Averitas Pharma Inc. | 2 | $43 |
| Vertex | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Smith+Nephew | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
How this compares
$5,689 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $75,620 |
| JardianceEmpagliflozin | 31 | $43,933 |
| EliquisApixaban | 43 | $39,920 |
| MounjaroTirzepatide | 23 | $34,856 |
| TrulicityDulaglutide | 14 | $19,595 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,340 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,530 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,331 |
| Novolog FlexpenInsulin Aspart | 24 | $3,419 |
| Atorvastatin Calcium | 335 | $3,329 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $2,101 |
| Novolin NInsulin Nph Human Isophane | 12 | $1,996 |
| Rosuvastatin Calcium | 158 | $1,657 |
| Losartan Potassium | 150 | $1,493 |
| Bupropion XlBupropion Hcl | 46 | $1,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $422 | $75,62053 claims |
| Lilly USA, LLCMounjaro, Trulicity | $340 | $54,45237 claims |
| Boehringer IngelheimJardiance | $302 | $43,93331 claims |
| PfizerEliquis | $380 | $39,92043 claims |
| GSKBreo Ellipta | $423 | $12,34025 claims |
| AstraZenecaSymbicort | $459 | $5,53018 claims |
| AbbVieSynthroid | $459 | $1,42617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Winter Haven
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.